项目建成后，可为社会提供更多高质量的原料药及中间体，满足国内外市场对创新药物日益增长的需 求，同时带动地方就业、促进产业集聚，为长三角医药创新与制造高地建设注入新动力。 开工仪式上，中建三局三公司党委书记、董事长王延波表示，公司将充分发挥全产业链整合、核心技术 支撑与精细化管理优势，集结最优管理团队、专业技术力量与精良施工队伍，严格遵循"安全第一、质 量至上、进度可控、绿色环保"理念，高标准规划、高质量建设、高效率推进，为绍兴乃至长三角医药 产业高质量发展注入新动能。 项目规划总建筑面积约10万平方米，涵盖多个生产车间、甲类与丙类仓库等配套建筑。项目聚焦高端原 料药及医药中间体的研发与生产，产品涵盖抗肿瘤、抗感染、心血管系统、肠外营养代谢等多个重大疾 病治疗领域，包括丙氨酰谷氨酰胺、氟康唑、地高辛、托吡卡胺等44个品种，年设计总产能约1075吨。 12月8日，由中建三局三公司承建的绍兴民生医药股份有限公司搬迁提升集聚建设项目在浙江省绍兴市 上虞工业园正式开工。该项目是绍兴市推进化工产业集约化、绿色化转型的重要示范工程，也是企业迈 向高端原料药领域、实现技术升级与产能整合的关键布局。 ...

Group 1: Company Overview - The company primarily engages in the research, production, and sales of nutritional health foods (including raw materials and finished products) and feed additives [2][3] - The production of health food raw materials and feed additives mainly occurs domestically, with a high export ratio; finished health food products are primarily produced and sold overseas, showing significant growth through cross-border e-commerce [3] Group 2: Product Development and Market Position - The company utilizes synthetic biology as a foundational technology for large-scale production of various raw materials, including Coenzyme Q10, NMN, NADH, Vitamin K2, and others [3] - Coenzyme Q10 holds the largest global market share, demonstrating notable cost and scale advantages [3] - The company aims to reduce production costs for products like astaxanthin, DHA, and EPA to enhance market competitiveness [3] Group 3: Brand and Sales Strategy - The company owns two major health food brands, Doctor's Best and Zipfizz, with production capabilities for capsules, tablets, and powders [3][4] - Doctor's Best is a well-known health brand in North America, showing steady growth, while Zipfizz maintains stable performance with new products developed for the U.S. market [4] - The marketing strategy for domestic health food business focuses on market insights, product strategy, resource integration, and data-driven upgrades to create market-leading products [4] Group 4: Financial Performance - The company's performance growth in the first half of 2025 is primarily attributed to increased sales of Coenzyme Q10, vitamins, and domestic health products [3]